Daily Markup

Daily Markup #954: Pandorum secures US$11M to advance their ‘liquid cornea’ technology for treating corneal blindness in humans

March 26, 2024 · 2 min read
Photo credit: Pandorum Technologies

A sight for sore eyes

  • Millions worldwide are waiting for donor tissues to cure corneal blindness. The odds are not in their favor, but one 500-backed biotech company is tipping the scales.
  • Pandorum Technologies successfully secured a US$11M pre-Series B to advance their flagship product, Kuragenx, dubbed ‘liquid cornea’, an innovation that can treat corneal blindness.
  • They aim to progress towards the first human studies using Kuragenx, and adapt the technology’s regenerative potential for liver, lung and neuronal tissues.
  • Founded by Arun Chandru & Dr. Tuhin Bhowmick, Pandorum has R&D labs in Bangalore, India and the USA, and works with prominent global partners.
  • “We are thrilled to have the support of the notable investors as we continue to innovate and develop therapeutics to restore healthy tissue functions, in order to help the patients suffering from unmet clinical needs,” Tuhin shared.
  • “Our flagship product Kuragenx combines proprietary biomaterials with regenerative nanotherapy, guiding the formation of a functional corneal tissue to restore vision. This is a first-in-class approach that can truly blur the line between treatment and cure,” he added.
  • “Giving back vision with something made in the lab, without depending on donor corneas, is truly transformative. This will positively impact millions of lives,” said Arun.
  • Congratulations to the Pandorum team!
  • Read the full story here.
Daily
Tags:
0
Share
• • • KEEP READING

Daily Markup

  • Daily Markup is brought to you by 500 Southeast Asia & 500 Global

  • This website is updated as of August 3, 2022. All content herein is intended solely for general informational or educational purposes only. 500 Startups Management Company, L.L.C. and its affiliates (collectively “500 Startups”) makes no representation as to the accuracy or information in this post and while reasonable steps have been taken to ensure that the information herein is accurate and up-to-date, no liability can be accepted for any error or omissions. All third party links in this post have not been independently verified by 500 Startups and the inclusion of such links should not be interpreted as an endorsement or confirmation of the content within. Information about portfolio companies’ markets, competitors, performance, and fundraising has been provided by those companies’ founders and has not been independently verified. Under no circumstances should any content in this post be construed as investment, legal, tax or accounting advice by 500 Startups, or an offer to provide any investment advisory service with regard to securities by 500 Startups. No content or information in this post should be construed as an offer to sell or solicitation of interest to purchase any securities advised by 500 Startups. Prospective investors considering an investment into any 500 Startups fund should not consider or construe this content as fund marketing material. The views expressed herein are as at the date of this post and are subject to change without notice. One or more 500 Startups fund may have a financial interest in one or more of the companies discussed

    All users of this website should note these important Terms of Use governing the use of this website.

  • Copyright © 2022 500 Global | All Rights Reserved

  • Privacy Policy
    Terms of Use
    Code of Conduct